Program
cefepime-zidebactam
Also written as “WCK 5222”, “Cefepime-Zidebactam” and “Cefepime-zidebactam (FEP-ZID)”.
Its studies are mostly in Pneumonia, Bacterial · Pyelonephritis · Renal Insufficiency, led by Wockhardt.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Wockhardt | 41 open or running | phase 3since Jul 5, 2021 | Oct 20, 2016 | Dec 31, 2027phase 3 · NCT07885891 |
Also a collaborator on its studies: medpace-inc and clinartis.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 20, 2016First study: phase 1 study in Renal InsufficiencyFirst studyNCT02942810 · 48 enrolled · United States
- May 16, 2018Phase 1 study in QT/QTc Interval in Healthy VolunteersNCT03554304 · 60 enrolled · United States
- Jul 5, 2021Phase 3 study in Complicated Urinary Tract InfectionNCT04979806 · 530 enrolled · United States, Bulgaria, China and more
- Sep 21, 2026Phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)NCT07885891 · 324 planned · Bosnia and Herzegovina, Bulgaria, Croatia and more
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)NCT07885891
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07885891Hospital Acquired Bacterial Pneumonia (HABP) · Bosnia and Herzegovina, Bulgaria, Croatia and more | 3 | Not yet recruiting | Dec 31, 2027 | 324 |
| NCT04979806Complicated Urinary Tract Infection · United States, Bulgaria, China and more | 3 | Completed | Nov 25, 2024 | 530 |
| NCT03554304QT/QTc Interval in Healthy Volunteers · United States | 1 | Completed | Jun 5, 2017 | 60 |
| NCT02942810Renal Insufficiency · United States | 1 | Completed | Apr 2017 | 48 |
How it is read
Names in the registry
- “WCK 5222”, 2 entries
- “Cefepime-Zidebactam”, 1 entry
- “Cefepime-zidebactam (FEP-ZID)”, 1 entry
Conditions, from the studies’ own filings
- Pneumonia, Bacterial, 1 study
- Pyelonephritis, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.